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Citrullination is a calcium-dependent process catalysed by a family of enzymes known 
as peptidylarginine deiminases (PADIs). PADI type II (PADI2) is strongly linked with the 
autoimmune disease rheumatoid arthritis, but more recently it has become an attractive 
research target due to its link with cancer. PADI2 overexpression is found in multiple 
myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) 
patients. In this report, we aim to determine the nature of citrullinated proteins in bone 
marrow stromal cells (BMSCs), the effect this has on their function, and the effect of 
hypoxia on PADI2 expression. Citrullinated proteins were analysed by immunoblot 
analysis of HS-5 and HEK293T cell lines after addition of either calcium to stimulate 
PADI2 activity, or EDTA to inhibit it. HS-5 cells were placed into hypoxic conditions (1% 
oxygen) for up to 32 hours and analysed by an immunoblot to detect changes in PADI2 
expression. The data from this study highlights changes in citrullination between 
calcium and EDTA treated cells in the HS-5 and HEK293T cell lines. Additionally, 
PADI2 expression is increased in HS-5 cells after two hours, and maintained after six 
hours in hypoxia, suggesting hypoxic conditions have an impact on PADI2 activity, and 
therefore, citrullination. In MM, hypoxia is known to have an effect on the malignant 
plasma cells, allowing them to migrate and home to new areas of the bone marrow 
(BM). Although in its initial stages, this study has begun to expand our understanding of 
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1.1. Multiple myeloma  
Multiple myeloma (MM) is a disease predominantly found in patients over 60 years old 
(Hulin et al., 2009). It is a haematological malignancy characterised by infiltration of 
malignant plasma cells in the bone marrow (Hideshima et al., 2007) and is associated 
with an accumulation (>10% increase) of monoclonal protein (M-protein) in the blood. 
Clinical indicators of MM comprise osteolytic bone lesions, renal failure, hypercalcemia, 
anemia, peripheral neuropathy (Korde et al., 2011) and an increased susceptibility to 
infection (Alexander et al., 2007). With around 4,000 new cases every year in the UK, 
MM accounts for approximately 10% of haematological cancers and contributes to 
approximately 1% of all cancers (Mutis, 2012).  
 
When a B cell encounters an antigen, it migrates to the germinal centre, known as the 
primary immune response. Here it matures via somatic hypermutation or antigen 
selection, followed by a class switch recombination to produce immunoglobulin 
isotypes (Morgan et al., 2012). The B cell, now a plasmoblast, migrates to the bone 
marrow (BM) where it finds a receptive niche to support its growth and survival as an 
antibody-producing plasma cell (Morgan et al., 2012). However, genetic alterations 
taking place along this route, interfere with the interactions of the plasma cell with the 
BM microenvironment. 
 
Monoclonal gammopathy of undetermined significance (MGUS) is the asymptomatic, 
premalignant condition of MM (Manier et al., 2012). The majority of MM cases are 
preceded by MGUS, however, some cases may arise de novo (Manier et al., 2012). 
For the cell to proceed from a normal plasma cell to MGUS a number of early 
oncogenic events takes place; namely cyclin D dysregulation (causing cell cycle 
progression), hyperdiploidy, primary IgH translocations and epigenetic abnormalities 
(Landgren and Waxman, 2010). Later, the plasma cells undergo further oncogenic 
events such as RAS mutations (the main genetic difference between MGUS and MM, 
as RAS mutations occur in only 5% of MGUS patients versus 40-55% in MM patients 
(Chng et al., 2008)), nuclear factor kappaB (Nf-κB) activating mutations (Bharti et al., 
2004), C-MYC rearrangements (Chesi et al., 2008) and tumour suppressor p53 (Neri et 
al., 1993), PTEN (Chang et al., 2006) and retinoblastoma (Rb) gene (Walker et al. 
2010) inactivation, to present MM. Biological transition of MGUS to MM occurs at a rate 




It was originally thought that MM was acquired through a linear fashion of genetic 
mutations, but further research has discovered more recently that this may not be 
correct. During the later stages of disease progression, some malignant plasma cells 
gain a clonal advantage allowing them to expand and further evolve into new niches 
within the BM (Morgan et al., 2012). This eventually creates an environment more 
suitable for malignant plasma cells, rather than the normal cells. Thus, tumour cell 
survival is strongly dependent upon the BM microenvironment (Manier et al., 2012). 
The MM cells lead on to become independent, no longer relying on the BM 
microenvironment and can be found at extramedullary sites and as circulating 
leukaemic cells (known as plasma cell leukaemia), which quickly results in patient 
fatality (Morgan et al., 2012).  
 
1.2. The bone marrow microenvironment in cancer 
To support tumourigenesis, the BM microenvironment is suitably specialised, rich with 
the resources needed for signalling and growth. Late stage adenocarcinomas, which 
originate from tumours that include breast, lung, prostate and kidney, metastasise to 
the BM where the disease becomes incurable and allows cancer cells to avoid 
chemotherapeutic agents (Olechnowicz and Edwards, 2014). However, changes to 
constituents of the BM microenvironment have been hypothesised to occur before the 
arrival of any metastatic cells, as the new microenvironment must be well adapted to 
support the growth and survival of the tumour (Kaplan et al., 2005). Consequently, 
novel therapies proposed aim to imbalance the supportive BM microenvironment rather 
than directly target the cancer cells (Olechnowicz and Edwards, 2014).  
 
Fibroblasts/BM stromal cells (BMSCs), osteoclasts and osteoblasts are all important 
cellular components of the BM niche (Hideshima et al., 2004). It is important to note 
that malignant plasma cells are able to home to the BM and adhere to the BMSCs and 
extracellular matrix (ECM) proteins, such as fibronectin and type I collagen. This 
adhesion process causes upregulation of cell cycle regulatory proteins and activates an 
anti-apoptotic cascade (Hideshima et al., 2004). Inflammatory cytokines are key 
players in modulating mobility of BMSCs to the site of the tumour. Cytokines and 
chemokines, such as IL-6 (interleukin 6), IL-8, SDF-1 (stromal derived factor 1), and 
MCF-1 (monocyte chemoattractant protein 1), stimulate tumour growth and maintain an 
inflammatory response (Spaeth et al., 2008). Furthermore, cytokines are important in 
epithelial-mesenchymal-transition (EMT) processes by activation of the β-catenin 




of decreased oxygen availability within the BM microenvironment (Grivennikov et al., 
2010). 
 
1.3. The bone marrow microenvironment in multiple myeloma 
Paracrine and autocrine cytokine production is essential for MM progression. IL-6 
causes B-cell differentiation in normal physiology (Pratt, 2002). Moreover, in myeloma, 
it is the most important inflammatory cytokine, aiding growth and survival of malignant 
plasma cells (Pratt, 2002). IL-1β is abnormally produced when malignant plasma cells 
adhere to the BMSCs, causing upregulation of IL-6 release from BMSCs (Dinarello, 
2011). IL-6 not only supports the growth and survival of the plasma cells (via the 
STAT3 and ERK pathways (Honemann et al., 2001)), but also enhances vascular 
endothelial growth factor (VEGF) production for angiogenesis (Podar and Anderson, 
2005) and inhibits antigen presentation of dendritic cells (Manier et al., 2012). IL-6 
inhibits the anti-proliferative effects of cyclin-dependent kinase (CDK) inhibitors such as 
p21, via the PI3K/Akt pathway (Hideshima et al., 2001). As a result, increased serum 
IL-6 in MM patients reflects an increase in the proliferation rate of malignant plasma 
cells and represents a poorer prognosis for patients (Manier et al., 2012).  
 
Stromal derived factor-1 (SDF-1) and its chemokine receptor, CXCR4 (present on the 
surface of the malignant plasma cells), have been shown to induce MM migration in 
vitro and BM homing in vivo (Alsayed et al., 2006). CXCR4 inhibitors have been found 
to prevent migration, suggesting that they play an important role in homing regulation in 
MM (Alsayed et al., 2006). Consequently, mobilisation of plasma cells out of the BM 
may be feasible by SDF-1/CXCR4 disruption (Manier et al., 2012). 
 
1.4. Citrullination 
A series of post-translational modifications (PTMs) occur during the progression of MM 
such as: methylation, acetylation, glycosylation and ubiquitination (Burska et al., 2014). 
A further interesting change the BMSCs undergo is an irreversible phenotypic alteration 
known as citrullination. Previous datasets in the Tennant research group have 
suggested that citrullination may be increased in BMSCs of MGUS and MM patients 
(unpublished data). Citrullination is a calcium-dependent process (Cordova et al., 2013) 
that converts a positively charged arginine residue into a neutral citrulline, by loss of 
the H2N
+ group (Christophorou et al., 2014), shown in figure 1.1. As a result, 
citrullination often causes an abnormal protein conformation (Shelef et al., 2012), 
leading to destabilisation of the intramolecular and intermolecular interactions 




binding properties and causes alterations to protein function and half-life (Chirivi et al., 
2013). For example, partial citrullination of the chemokine CXCL12 has a significant 
impact on binding to its receptor, CXCR4, whereas complete citrullination of CXCL12 







Figure 1.1. – Representation of citrullination, a process that converts a positively 
charged arginine residue into a neutral citrulline residue, catalysed by PADI enzymes in 
the presence of calcium (Mohanan et al., 2012). 
 
It has been acknowledged that citrullination plays a role in autoimmune diseases such 
as multiple sclerosis (MS) and rheumatoid arthritis (RA) (Vossenaar and Robinson, 
2005). Citrullinated proteins are recognised as ‘non-self’ and, therefore, produce an 
inflammatory response (Tanikawa et al., 2009). Anti-citrullinated protein antibodies are 
produced before the onset of disease, and may be therapeutically administered to 
prevent further inflammation or used as a diagnostic biomarker (Chirivi et al., 2013). It 
is clear citrullination plays a role in inflammatory processes in normal physiology and 
not only in autoimmune disease. To support this, a study by Coudane et al. (2011) 
demonstrated citrullination in a non-autoimmune inflammatory event Coudane et al., 
2011). 
 
1.5. Peptidyl arginine deiminases 
A family of enzymes known as peptidyl arginine deiminases (PADI) catalyse 
citrullination (Shelef et al., 2012). Within the PADI family are five conserved subtypes: 
PADI type I, II, III, IV and VI (Wang and Wang, 2013), clustered on chromosome 1p35-
36 (Chavanas et al., 2004), that each have specific tissue distributions (Wegner et al., 




Table 1.1. – An example of protein citrullination in healthy physiology versus the 
pathological physiology, demonstrating the effect of aberrant citrullination compared to 
normal citrullination. 
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PADI type I is found expressed in the epidermis and uterus and specifically targets 
keratin and filaggrin (Ishida-Yamamoto et al., 2002). Type II, focussed on here, is 
widely expressed and is detected across a wide range of mammalian tissues (see 
below). Type III is also found within the epidermis and in hair follicles, targeting filaggrin 
and trichohyalin (Nachat et al., 2005). Type IV has been found in white blood cells and 
tumours, targeting nuclear proteins (Nakashima et al., 2002). Type VI is one of the 
least studied subtypes, although it is known to be present in mammalian ovaries, eggs 
and embryos (Wright et al., 2003). As demonstrated in table 1.1, aberrantly citrullinated 
proteins are present in a range of diseases. Each of the PADI subtypes, except PADI 
type III and VI, have been implicated in pathological disease (Wang and Wang, 2013). 
 
Of the five PADI enzymes, PADI type IV (PADI4) has been most widely studied. PADI4 
is localised within the nucleus and predominantly citrullinates nuclear proteins such as 
histones. Other modifications such as histone methylation can alter gene expression. 
There is evidence to suggest that changes in methylation of histones plays an 
important role in tumourigenesis (Martinez-Garcia et al., 2011). Methylated histones 
regulate chromatin structure and function; however, PADI4 has the ability to antagonise 
histone methylation, converting methyl-arginine to citrulline by targeting sites in the tails 
of histones H3 and H4 (Denis et al., 2009). Consequently, PADI4 has been 
increasingly studied and has subsequently been implicated in cancer. PADI4 has been 
recognised in breast cancer cell lines, such as MCF-7s, where it may play a role in 
gene transactivation (Zhang et al. 2011). Stadler et al. (2013), found that in non-
invasive MCF-7 cell lines, PADI4 activity reduces EMT and also decreases invasion 
potential. Nevertheless, increased PADI4 has been found in patients with malignant 
tumours compared to non-malignant control patients and has, therefore, been 
implicated in tumourigenesis progression (Chang et al., 2009). PADI4 expression is 
regulated by oestrogen to mediate the oestrogen response and, additionally, epidermal 
growth factor receptor (EGFR) signalling in breast cancer (Zhang et al., 2011). Liu et al. 
(2006) demonstrated that reduced or depleted PADI4 causes raised p21 expression, 
leading to apoptosis via the p53 pathway (Liu et al., 2006). Cherrington et al. (2012) 
established that a sub-population of PADI2 localises to the nucleus of MCF-7 cells 
where it can bind chromatin (Cherrington et al., 2012). Depletion of PADI2 suppresses 
MCF-7 proliferation and, therefore, potentially plays a role in breast cancer 
development (Cherrington et al., 2012). In addition, it has been proposed that PADI2 
and PADI4 may function synergistically. Recent findings identified PADI2 




phenomenon should, therefore, be investigated further to determine the effect these 
enzymes propose on tumour progression  (Monohan et al., 2012). 
 
Although most research has been conducted on PADI4, the recent findings that PADI2 
also plays an important role in citrullination of histones (Wang and Wang, 2013) and its 
association with gene regulation in breast cancer (Cherrington et al., 2012) has made it 
an attractive target for research.  
 
1.6. PADI type II 
PADI2 is widely expressed and found in the following: brain astrocytes, sweat glands, 
skeletal muscle, spinal cord tissue, macrophages and the epidermis (Foulquier et al., 
2007; Wang and Wang, 2013). Substrates known to be citrullinated by PADI2 include: 
myelin basic protein (Lamensa and Moscarello, 1993), vimentin (Schett and 
Gravallese, 2012), histones (H3 and H4) (Cherrington et al., 2012), β and γ-actins 
(Darrah et al., 2012), fibronectin, fibrinogen (Tabushi et al., 2008) and collagen 
(Yoshida et al., 2006).  
 
Studies, such as that carried out by Cherrington et al. (2012), found that PADI2 
expression in human mammary gland epithelial cells is able to citrullinate histone H3 at 
the N-terminus. PADI2 is able to associate with oestrogen receptor alpha to facilitate its 
translocation from the cytoplasm into the nucleus; however, PADI2 nuclear localisation 
appears to be reduced as the tumour progresses (Cherrington et al., 2012). It is likely 
that PADI2 activates target gene transcription when the cell responds to oestrogen 
stimulation (Zhang et al., 2012) suggesting that PADI2 can act as an epigenetic 
regulator, controlling gene activity. In addition to the links that have been made with 
PADI2 and cancer, it has been proposed that PADI2 regulates macrophage cytokine 
signalling by deimination of IKKγ (forms part of the cytokine responsive IKK complex 
which regulates NF-κB activity (Rothwarf et al., 1998) and, therefore, cell proliferation 
and survival) (Lee et al., 2010). 
 
Although little is known about citrullinated fibronectin, it is evident that it has a higher 
affinity for VEGF and decreases the ability to cause apoptosis in a leukaemic cell line, 
such as HL-60 (Chang et al., 2005). Mohanan et al. (2012) hypothesises that 
citrullinated vimentin promotes an inflammatory milieu and affects cell migration of 
tumour cells. It has recently been found that Cl-Amidine is a successful pan PADI 
inhibitor, allowing inflammatory symptoms to be obstructed (Slack et al., 2011). PADI2 




demonstrate treatment of tumour cells with Cl-Amidine, reduce cancer cell viability 
separate from normal cell growth (Slack et al., 2011).  
 
Citrullination by PADI2 plays a crucial role in inflammatory processes and is induced in 
a range of pathologies (Mohanan et al., 2012) including psoriasis (György et al., 2006), 
alzheimers disease (Ishigami et al., 2005) and multiple sclerosis (MS) (Vossenaar et 
al., 2003). However, PADI2 expression has most particularly been linked with RA 
(Wang and Wang, 2013). 
 
1.6.1. PADI type II in rheumatoid arthritis 
RA is an autoimmune disease, generating an immune response against self-antigens 
and is characterised by synovial inflammation of the joints (Shelef, 2012), infiltration of 
macrophages (Kinne et al., 2000), hyperplasia (McInnes and Schett, 2011) and the 
presence of autoantibodies (specifically anti-citrullinated protein antibodies (ACPAs)) 
(Song and Kang, 2010). Inflammation causes the joints to become painful and 
eventually leads to cartilage and bone destruction (Shelef, 2012). Leukocytes infiltrate 
the synovial tissue of RA patients and release PADI2 and PADI4 in the synovial fluid, 
causing an influx of citrullinated proteins (Kinloch et al., 2008). The presence of 
citrullinated proteins within the synovial fluid of the joint initiates a ‘false’ immune 
response causing immune cells to generate ACPAs (Wegner et al., 2010).  
 
In a study by Fan et al. (2012), it has been recognised that citrullination of vimentin has 
significant biological effects in RA patients. This is due to evidence of stimulation of 
proliferation, pro-inflammatory cytokine secretion (TNF-α and IL-1) and upregulation of 
PADI4 and RANKL (promotes osteoclast maturation and activation (McInnes and 
Schett, 2011)) expression in fibroblast-like synoviocytes (Fan et al., 2012), leading to 
bone erosion (McQueen and Issa, 2013). Furthermore, fibronectin is an important 
protein that regulates many cell behaviours including migration, adhesion, invasion and 
survival (Shelef et al., 2012). Fibronectin, an ECM protein known to be citrullinated by 
PADI2, also plays an important role in synovial fibroblast behaviour, as it increases 
synovial fibroblast adhesion to cartilage (Shiozawa et al., 1992). Shelef et al. (2012) 
concluded from their study that citrullination of fibronectin leads to impaired migration, 
adhesion, spreading and integrin-mediated signaling in synovial fibroblasts (Shelef et 
al., 2012). It is possible that the citrullination of proteins causes aberrant adhesion, 
leading to the metastasis of cells, increased RA spread and further joint destruction 





The weight of evidence suggests protein citrullination has a pathogenic role (Shelef et 
al., 2012). The level of citrullination appears to be affected by inflammation, as 
demonstrated by Makrygiannakis et al. (2006), who showed that glucocorticoids, 
administered locally, reduced citrullination in the joints of patients with rheumatoid 
arthritis. To support this, Foulquier et al. (2007) demonstrated that PADI expression in 
the synovial tissue of RA patients is an inflammation-dependent process.  
 
Patients with autoimmune diseases are thought to be at an increased risk of cancer, 
compared to the general population. This may be due to the dysregulation of the 
immune system (Hemminki et al., 2012) in autoimmune diseased patients. More 
specifically, Abu-Shakra et al. (2001) discuss how there is an increased risk of 
haematological malignancies in RA patients. RA has been strongly associated to other 
inflammatory diseases (McInnes and Schett, 2011), particularly cancer; nonetheless, 
this remains extremely controversial (Shen et al., 2014).  
 
1.6.2. PADI type II in multiple myeloma 
Although links have been made between PADI2, cancer and other inflammatory 
pathologies, in terms of MM, little is known about the activity of PADI2 although, it has 
been suggested that RA patients may be at a higher risk of MM development. This is, 
however, inconclusive (Shen et al., 2014). Due to the similarities between RA and MM 
physiology, by applying the substantial knowledge we currently have of the 
pathophysiology and role PADI2 plays in RA, and transferring it to the pathophysiology 
of MM, this could potentially aid our understanding of the role it plays in the BM 
microenvironment of MM patients. 
 
To support this, a preliminary data from studies carried out in the Tennant research 
group showed PADI2 expression was elevated in MGUS and MM patients compared to 
that seen in control patients, suggesting that it may have a role in the pathogenesis of 
MM. During the transition of an arginine residue to form citrulline by PADI2, an 
ammonia group is released and converted into urea. It was found that urea 
concentration was significantly increased in the BM of patients with MGUS and MM 






Figure 1.2. – Citrullination of proteins in control, MGUS and MM patients. A: 
expression of PADI2 in control, MGUS and MM. B: Urea concentration within the BM of 
control, MGUS and MM. C: Representation of the citrullination mechanism. (Tennant et 
al., unpublished data) 
SLC14A1 is a urea transporter gene, important for regulating osmosis (Garcia-Closas 
et al., 2011). Further preliminary data also found that, as demonstrated in figure 1.3, 
SLC14A1 is upregulated in the BM plasma of MGUS and MM patients, significant to 
0.0001 (calculated by a Kruskall-Wallis statistical test). This additionally supports that 
there is PADI activity, as SLC14A1 is upregulated to transport urea out, eliminating it 









Figure 1.3. – Representation of the changes in SLC14A1 (urea transporter) gene 







In normal conditions, the supply and metabolic consumption of oxygen is balanced to 
meet the demands of the tissue. Hypoxia is the term given when the balance is 
disturbed, causing the supply of oxygen unable to meet the consumption needed for 
metabolic processes. Hypoxia is a characteristic feature of solid tumours and can aid in 
tumour progression and drug resistance (Vaupel and Mayer, 2007). HIF 1-alpha (HIF1-
α) and 2-alpha (HIF2-α) regulate gene expression in glycolysis and angiogenesis. 
Under normal conditions, HIF concentration is maintained at low levels, whereas; under 
hypoxic conditions, HIFs are upregulated due to degradation inhibition and accumulate 
within the cell (Giatromanolaki et al., 2010). 
 
1.7.1. Hypoxia and multiple myeloma 
Hypoxia promotes metastasis via regulation of proteins involved in EMT. When these 
proteins are activated, E-cadherin (CDH1) is lost, resulting in decreased adhesion of 
malignant plasma cells in MM (Azab et al., 2012) enabling them to metastasise. 
Additionally, hypoxia increases CXCR4 expression allowing the plasma cells to migrate 
and home to new areas of the BM. This allows the MM cells to recover (Azab et al., 
2012). 
 
1.7.2. Hypoxia and PADI type II 
In a study carried out by Sambandam and colleagues (2004), it was discovered that in 
astrocytes, PADI2 expression is increased during progressively longer hypoxic 
conditions. PADI2 mRNA expression is increased and maintained throughout a 16 hour 
time window after 2 hours under hypoxic conditions. This later resulted in glial fibrillary 
acidic protein (GFAP) citrullination. Therefore, in relation to MM, it would be interesting 
to investigate whether PADI2 expression is increased in a fibroblast cell line (such as 
HS-5), causing increased citrullination during hypoxic conditions. Although, it must be 
noted that in some cell lines, citrullination has been seen to cause apoptosis (Gong et 
al., 1999). 
1.8. Objective and aim 
Investigations into the role of PADI2 in MM permit a clearer understanding of the 
interactions that take place between MM and BMSCs. Determining the effect that 
citrullination by PADI2 has on the interactions in the BM microenvironment will allow 
further preventative or therapeutic approaches to be identified. Taking what is known 




plays an important role within the BM microenvironment, as it does within the synovial 
joint in RA. 
 
Therefore, the objective of this study is to investigate the phenomenon of citrullination 
as a method by which BMSC’s dictate their BM microenvironment to determine disease 
progression. The aim of the study is to determine the nature of proteins that are 
citrullinated, to examine the effect of this citrullination on their function and to determine 
































2. Materials and Methods  
All materials were obtained from Sigma-Aldrich, unless otherwise stated. 
 
2.1. Antibodies 
Primary antibodies were incubated at 4°C overnight at the stated concentrations:  
Polyclonal anti-PADI2, 1:500 (Abcam®), monoclonal Z-22 anti-PADI2, 1:100 (Santa 
Cruz Biotechnology®), polyclonal anti-PADI2, 1:500 (Proteintech™), polyclonal anti-
citrulline 1:1000 (Abcam®) and clone 54 anti-HIF1-α 1:500 (BD Biosciences). For 
determining equal loading, membranes that used the same secondary antibody were 
stripped gently with 0.1% sodium azide and probed with monoclonal AC-40 anti-β-actin 
1:4000 (Sigma-Aldrich).  
Secondary antibodies used include anti-rabbit horseradish peroxidase (HRP)-linked, 
1:4000 (Cell Signalling) and anti-mouse HRP-linked, 1:4000 (Cell Signalling). 
 
2.2. Cell culture 
2.2.1. Cell lines 
Cell lines used include BMSCs (HS-5) (ATCC®), astrocytes (U87 MG) (CLS Cell Lines 
Service), U87 isocitrate dehydrogenase 1 (IDH1) mutant (Pim French, Bralten et al. 
2011), breast tissue cells (MCF10A’s, MCF7’s (ATCC®), BT474 (Clare Davies, 
University of Birmingham)) and human embryonic kidney cells (HEK293T) (Clare 
Davies, University of Birmingham). 
 
2.2.2. Transfections 
DMEM (Hyclone™, Healthcare Life Sciences, UK) containing L-glutamine (Hyclone™, 
Healthcare Life Sciences, UK) and fetal bovine serum (FBS) (Hyclone™, Healthcare 
Life Sciences, UK) (10%) were used to culture the HEK293T cell line and RPMI 
medium containing sodium pyruvate for the HS-5 cell line. Cells were seeded 24 hours 
prior to transfection. As shown in table 2.1, jetPEI® DNA transfection reagent (polyplus-



























6 well 3 2 x 10
5 
6 100 3 
10cm 7 2 x 10
6 
30 250 10 
 
Sodium chloride (NaCl) was added together with jetPEI® and separately with the 
plasmid DNA, each vortexed for 10 seconds. The tubes were combined, always adding 
jetPEI® to the DNA, and vortexed for a further 10 seconds, followed by a 30 minute 
incubation period at room temperature. The transfection mix was added to the cells and 
incubated at 37°C overnight. 
 
2.2.3. Harvesting cells  
Media was removed from seeded cells before 1ml 1x phosphate buffered saline (PBS) 
was added. Cells were scraped with a sterile cell lifter (Fisher Scientific UK) into PBS 
using a sterile cell scraper, and transferred into an eppendorf. These were centrifuged 
at 1,500 x g for ~8 minutes and the supernatant discarded. Some transfected cells (to 
check for PADI2 expression and citrullination) were resuspended in 1x Laemmli (50μL) 
and boiled for 5 minutes before freezing, whereas others were flash frozen, using dry 




2.3.1. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)  
Each sample was lysed in lysis buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% triton 
and 1:100 protease cocktail inhibitor (PIC)) and centrifuged at 13,000 x g for 5 minutes. 
The supernatant (soluble) was separated and 1x Laemmli buffer (SDS-PAGE sample 
buffer) added before boiling for 5-10 minutes to denature the soluble proteins. The 
samples were separated by SDS-PAGE, consisting of a 10% resolving gel and 4% 
stacking gel. Samples were loaded alongside a molecular weight marker Rainbow™ 
(GE Healthcare Life Sciences). Each gel was run at 150V for ~55 minutes. 
 
2.3.2. Protein transfer  
The SDS-PAGE gel was then transferred onto nitrocellulose membrane 




milk before the appropriate antibody was added. This was left for ~2-3 hours or 
overnight at 4°C. The membrane was washed quickly 3 times, followed by 3 further 
washes for 10 minutes each, before adding the appropriate secondary antibody. The 
wash steps were repeated after 1 hour. Once washed, the immuno-signals were 
visualised by adding enhanced chemiluminescence (ECL) (GE Healthcare) at a 1:1 
ratio and processed using a Konica Minolta developing unit. 
 
2.4. Endogenous PADI2 expression across different cell lines 
1mL of neutralised cell suspension was centrifuged at 13,000 x g for 5 minutes. Excess 
media was removed and 1x Laemmli buffer added before each sample was boiled for 5 
minutes for immunoblot analysis. Cell lines include: BT474 (positive control (Clare 
Davies, University of Birmingham)), HS-5, HEK293T, MCF10A, MCF7, U87 and U87 
IDH1 mutant. 
 
2.5. Immunoprecipitation of whole cell lysates 
25μL of Protein G Sepharose 4 Fast Flow beads (GE Healthcare Life Sciences) were 
added to an eppendorf and washed using 1mL wash buffer (50 mM Tris/HCl pH 7.5 
and 150 mM NaCl). The beads were centrifuged at 1,500 x g and the supernatant 
removed, followed by 2 further wash steps. Once washed thoroughly, 1mL wash 
buffer and the appropriate antibody was added (4μg/μL) to the beads and incubated 
at 4°C overnight on a rotating wheel. The beads were centrifuged at 1,000 x g for 2 
minutes and the supernatant removed. 1mL wash buffer was added and the beads 
centrifuged again. Once the supernatant was removed, the soluble lysate was added 
and incubated with the beads at 4°C for 2-4 hours on a rotating wheel. 3 wash steps 
were repeated and 1x Laemmli added, before boiling for 5 minutes and freezing at -
20°C until immunoblot analysis. 
 
2.6. Immunoprecipitation using covalently linked dynabeads® 
Harvested transfected cells were placed on ice to thaw then lysed with lysis buffer 
(20% triton, 50 mM Tris/HCl pH7.5 and 1:100 PIC) by resuspending and incubating on 
ice for 20 minutes. Cells were centrifuged at 13,000 x g for 10 minutes at 4°C. 40μL 
dynabeads® (Life Technologies™) were washed with wash buffer (50 mM Tris/HCl pH 
7.5 and 150 mM NaCl). The soluble lysed cells were added to the beads and incubated 
at 4°C for two hours on a rotating wheel. A further 4 washes were carried out before 
adding 2x Laemmli buffer, boiling for 5 minutes and freezing at -20°C for later 





2.7. Calcium/EDTA assay 
2.7.1. HEK293T cell line 
2 x 15 cm dishes of HEK293T cells were seeded at 1 x 106 and 1 x 15 cm dish 
transfected before harvesting (as previous). Non-transfected (control) and transfected 
(PADI2) cells were thawed on ice for 1 hour before being resuspended in 1mL 1x PBS. 
A 100μL fraction was removed from PADI2 transfected cells and placed into a separate 
eppendorf to check for PADI2 expression. Each tube was centrifuged at 1, 500 x g for 
~8 minutes, the supernatant was removed and 1x Laemmli buffer added to the 100μL 
fraction. The remaining 900μL PADI2 transfected cells and control cells were placed on 
ice for 20 minutes in lysis buffer (20 mM Tris/HCL pH 7.5, 100 mM NaCl, 10% glycerol, 
5 mM dithioerythritol (DTE), 10 mM β-mercaptoethanol, 1% triton and 1:100 PIC). Cells 
were spun back down at 13, 000 x g for 10 minutes and a 50μL fraction of the 
supernatant, from each PADI2 transfected and control cells were split between two 
tubes (~400μL) to provide the following: 
 
Control (untransfected cells): + Calcium (10 mM) 
    + EDTA (Fisher Scientific UK) (1 mM) 
PADI2 (transfected cells): + Calcium (10 mM) 
    + EDTA (1 mM) 
 
Each tube was left at 37°C for 3 hours, with a 50μL fraction removed at 30 minute 
intervals. Once removed, 50μL 2x Laemmli buffer was added to stop the reaction and 
the sample boiled for 5 minutes. Samples were frozen at -20°C until immunoblot 
analysis (adapted from Assohou-Luty et al., 2014). 
 
2.7.2. HS-5 cell line and recombinant PADI2 
Cells were plated on a 10 cm cell culture dish, seeded at 2.5 x 106 and left overnight at 
37°C before being scraped into 1mL 1x PBS and spun down at 1,500 x g for 8 minutes. 
The supernatant was removed and cell pellet aliquots frozen at -80°C. Cells were 
thawed on ice, before 200μL sonication buffer (20 mM Tris/HCL pH 7.5, 100 mM NaCl, 
10% glycerol, 5 mM dithioerythritol (DTE), 10 mM β-mercaptoethanol and 1:100 PIC) 
was added. The cells were sonicated for 5 seconds (25%), repeating 3 times, and 
cooling on ice between repetitions. A fraction (50μL) of the whole cell lysate (WCL) 
sample was removed as a control on an immunoblot analysis. EDTA (1 mM) was 
added to one aliquot of cell lysates and calcium chloride (10 mM) and 130 nM 
recombinant PADI2 protein added to another. The samples were incubated at 37°C for 




incubating, the protein G sepharose beads were washed in wash buffer (50 mM 
Tris/HCl pH 7.5) twice and once in sonication buffer. After washes, 1mL fresh 
sonication buffer was added before adding the α-citrulline antibody (1:100) and 
incubating at 4°C for 2 hours. The protein G sepharose beads were re-washed 3 times 
in wash buffer to remove excess/unbound antibody. Cell lysates were added to the 
protein G beads and the volume made up to 1mL with sonication buffer before 
incubating at 4°C for 2 hours. The sample was washed 3 times in sonication buffer 
(centrifuging at 1,000 x g for 1 minute at 4°C after each wash). 1x Laemmli was added 
and boiled for 5 minutes before immunoblot analysis or freezing at -20°C. 
 
2.7.3. HS-5 cell line and recombinant PADI2 with glycine elution 
The above experiment (2.7.3.) was repeated, however, Laemmli buffer was not added 
and an additional glycine elution step inserted to remove the protein from the beads. 
50μL 100 mM glycine (pH 2.3) was added to each eppendorf (+ Calcium/PADI2 and + 
EDTA) and left at room temperature for 10 minutes, agitating gently. The beads were 
spun down and the supernatant placed into a new eppendorf to produce the eluent. 
The eluent was neutralised with 10μL 1M Tris-HCl, pH 8. A 10μL aliquot of each 
sample was removed for immunoblot analysis (2x Laemmli and boiled for 5 minutes) 
and the remaining sample frozen at -20°C. 
 
2.8. HEK293T cell line transfected with recombinant PADI2 
 
Cells were plated at 2 x 106 on 3 x 10 cm cell culture dishes and used as follows:  
 
 Control (HEK293T cells) 
 Wild type recombinant PADI transfection 
 Inactive mutant C645S recombinant PADI2 transfection 
  
Transfections were carried out as indicated in section 2.2.2. Cells were harvested 24 
hours later, centrifuged at 1, 500 x g for 8 minutes and the supernatant discarded 
before adding 1x Laemmli buffer and boiling for 5 minutes. WCL’s were frozen at -20°C 
until immunoblot analysis.  
 
2.9. PADI2 expression in HS-5 cell line in hypoxia 
Cells were seeded at 2.5 x 106 onto 6 x 10 cm dishes and incubated overnight at 37°C. 




4hr, 6hr, 24hr, 32hr) cells were scraped into 1x Laemmli buffer (~60μL), boiled for 5 

























































3.1. Endogenous expression of PADI2 varies between different cell lines 
To determine endogenous PADI2 expression between cell lines, WCL of BT474, HS-5, 
HEK293T, MCF7, MCF10A, U87 and U87 isocitrate dehydrogenase 1 (IDH1) mutant 
were analysed by immunoblotting. Samples were separated by a 10% SDS-PAGE gel 
and probed with anti-PADI2 (Abcam), anti-PADI2 (Proteintech) and anti-β-actin as a 
















Figure 3.1. – Endogenous PADI2 expression varies between different cell lines. 
Immunoblot analysis of whole cell lysate of BT474, HS-5, HEK293T, MCF7, MCF10A, 
U87 and U87 isocitrate dehydrogenase 1 (IDH1) mutant samples. Samples were 
separated by a 10% SDS-PAGE gel and probed with (a) anti-PADI2 (Abcam), (b) anti-
PADI2 (Proteintech) and anti-β-actin as a loading control.  
 
The BT474 cell line was used as a positive control as it is known to have increased 
endogenous PADI2 expression (McElwee et al., 2012). Both the normal U87 cell line, 
and one expressing the tumourigenic IDH1 R132H mutation also express endogenous 
PADI2 whereas HS-5, HEK293T, MCF7 and MCF10A’s have little or no expression. 
However, the MCF7 and MCF10A cell lines in comparison to the others have 
decreased loading as demonstrated by the anti-β-actin loading control. Therefore, it is 





are required to determine this. It is clear by the BT474 and U87 lines that the anti-
PADI2 (Abcam) was specific, whereas, anti-PADI2 (Proteintech) appeared to be very 
unspecific making it difficult to detect where PADI2 is present.  
 
3.2. Transfection of PADI2 into HEK293T cells 
To ensure PADI2 could be transfected, cells were treated with jetPEI® transfection 
reagent and WCL were analysed by immunoblotting, probed with anti-PADI2 (Santa 












Figure 3.2. – PADI2 transfection into HEK293T cells was confirmed by immunoblot 
analysis. Cells were treated with jetPEI® transfection reagent, harvested, separated by 
a 10% SDS-PAGE gel and probed with anti-PADI2 (Santa Cruz Biotechnology®) and 
loading control anti-β-actin. 
 
PADI2 was successfully transfected into HEK293T cells, although it appeared smaller  
(~50 kD) than the known PADI2 size (75 kD). 
 
3.3. Immunoprecipitation in HEK293T cells 
3.3.1. Immunoprecipitation of PADI2  
To find whether PADI2 could be immunoprecipitated from HEK293T transfected cells, 
cells were treated with 1% triton to lyse cells, the soluble and insoluble fractions divided 
and the soluble fraction added to protein G sepharose beads with anti-PADI2 (Santa 
Cruz Biotechnology®) bound. Samples were separated using a 10% SDS-PAGE gel 
and immunoblotted (3.3 A). 
 
PADI2 appears to have been successfully immunoprecipitated from transfected 




the immunoprecipitation with molecular weights or 75 kDa (band 1) and 50 kDa (band 
2). Figure 3.3 A, band 1 most likely represents endogenous PADI2 (75 kDa), whilst 
band 2 represents the transfected DNA (50 kDa). 
 























Figure 3.3. – PADI2 has been successfully immunoprecipitated (IP) from HEK293T cell 
lysate (soluble fraction), although citrullinated proteins are difficult to identify. Cells 
were treated with 1% triton to lyse cells, and the soluble and insoluble fractions divided. 
Each fraction of the samples were separated by a 10% SDS-PAGE gel and 
immunoblotted. (A) Anti-PADI2 (Santa Cruz Biotechnology®) IP, 1 = correct PADI2 
size, 2 = the same size band seen in figure 3.2. (B) Anti-citrulline IP between HEK293T 
cells (control) and PADI2 transfected HEK293T cells (PADI2). (C) Anti-citrulline IP, 
carried out as above, however, using covalently linked dynabeads® to help reduce the 




3.3.2. Immunoprecipitation of citrullinated proteins 
Citrullinated proteins present in PADI2 transfected HEK293T cells were also 
immunoprecipitated, as above except using an anti-citrulline antibody (figure 3.3 B/C). 
As the result of using a whole antiserum anti-citrulline antibody, it was difficult to predict 
the best concentration to use for immunoprecipitation and, therefore, the heavy and 
light chain are too overexposed to visualise the bands (figure 3.3 B). Thus, covalently 
linked dynabeads® were used (figure 3.3 C), to help visualise the bands by helping to 
reduce the antibody heavy and light chain, although differences in the bands present 
between control and PADI2 on this IP are also difficult to analyse due to over-
exposure. 
 
3.4. PADI2 DNA is a truncated version 
It was surprising that we saw no difference in protein citrullination between control and 
PADI2 transfected cells. In addition, the PADI2 DNA used to transfect HEK293T cells 
in previous experiments appeared to be at the wrong size (approximately 50kD). 
Therefore DNA sequencing analysis was carried out to detect any abnormalities. As 
shown in figure 3.4, the PADI2 construct previously used is truncated by 223 amino 
acids. Critically, it is expected these residues contain the C-terminal domain. Studies 
have shown PADI4 to consist of two domains including the N-terminal and catalytic C-
terminal. Furthermore, it has been shown that each PADI shares approximately 50% 
sequence identity, and even greater similarity within the C-terminal (Arita et al., 2004); 




Figure 3.4. – Representation of domain structure of wild type (WT) PADI2 and 
truncated PADI2. WT PADI2 consists of two main domains; the N-terminal and catalytic 
C-terminal and is 1-663 amino acids (aa) in length (Arita et al. 2004). The truncated 






3.5. Calcium/EDTA assay 
3.5.1. The effect of increased calcium/EDTA in HEK293T cell line transfected 
with truncated PADI2 DNA 
Before it became apparent that the PADI2 DNA was truncated, two calcium/EDTA 
assays were carried out. Although, as previously mentioned, figure 3.3 A suggests that 
there is endogenous PADI2 present. It is, therefore, important to note that the following 
results seen are the outcome of endogenous PADI2 as any citrullination can only be 
the result of the catalytically active, endogenous PADI2. 
 
In an attempt to modulate PADI2 activity in HEK293T cells, cells were treated with 1 
mM EDTA, used to chelate calcium ions and inhibit PADI2 activity or 10mM calcium to 
stimulate PADI2 (due to its calcium-dependent nature) (Assohou-Luty et al., 2014). 
One aliquot of HEK293T cells (control) and one of PADI2 transfected HEK293T cells 
(PADI2) was lysed and the supernatant split between two tubes, one for the addition of 
calcium (control and PADI2) and the other for EDTA (control and PADI2). 20μL of each 
of the control and PADI2 transfected cells were taken for immunoblot analysis prior to 












Figure 3.5. – Immunoblot confirming transfection of PADI2 DNA into HEK293T cells. 
Each sample was separated by a 10% SDS-PAGE gel and probed with anti-PADI2 





















Figure 3.5.1. – Immunoblot analysis of calcium/EDTA assay in PADI2 transfected 
HEK293T cells (PADI2) and HEK293T cells (control). Adding SDS-PAGE sample 
buffer stopped each reaction. A 10% SDS-PAGE gel was used to separate the 
samples. Probes included anti-citrulline and anti-β-actin as a loading control. (A) Short 
exposure and 10 mM calcium (Ca2+). (B) Short exposure and 1 mM EDTA. (C) Long 
α- citrulline 
α-β-actin 





exposure of both Ca2+ and EDTA. (*) Represent bands that appear significant to PADI2 
transfected cells. 
 
Under stimulation of 10 mM calcium, control cells produce increased citrullination in an 
unknown protein approximately 100 kD (only bands visible under low exposure) up to 
approximately 150 minutes before decreasing, whereas PADI2 transfected cells only 
have a citrullinating effect up to 60 minutes.  
 
Control and PADI2 cells treated with 1 mM EDTA did not have the hypothesised effect 
of preventing citrullination by calcium chelation (hence, + Ca2+ 180 minute control); yet, 
do not follow the same trend as calcium stimulated cells, as the citrullination level, 
although lower, remains moderately maintained throughout.  
 
Under longer exposure, more bands are exposed. EDTA treated cells appear to have 
more citrullination occurring in control cells compared with PADI2. However, with 
added calcium, PADI2 has some significant bands (indicated by * in figure 3.5.1 C) 
appearing specific at 60 minutes.  This time point is also where the protein looks most 
citrullinated before citrullination is significantly decreased. 
 
As stated above, it is important to note that the transfected PADI2 is a truncated 
version and, therefore, the effects seen may be the result of full-length endogenous 
PADI2 present in the cells. Furthermore, the truncated version of PADI2 could possibly 
be having a dominant negative effect, which is discussed later. 
 










Figure 3.5.2. – Immunoblot analysis of repeated calcium/EDTA assay in PADI2 
transfected HEK293T cells (PADI2) and HEK293T cells (control), separated by a 10% 
SDS-PAGE gel, representing the difference in citrullination of proteins (anti-citrulline) 
and loading control (anti-β-actin).  
 
With regard to the changes observed in the citrullination of the unknown protein of 
approximately 100 kD, citrullination appears to remain constant with calcium 
stimulation in PADI2 transfected cells, whereas it slowly increases within the control. 
Although the loading control shows unequal loading between the two groups, they 
appear moderately even within each group. Therefore, it is unfortunately only possible 
to compare them to one another. As a result of this, it is difficult to conclude whether 
the bands that appear around 38 kD and 24 kD in both the calcium and EDTA are 
specific to PADI2 or if it was due to loading error. Citrullination within the PADI2 
transfected cells appear to increase slightly over time in both calcium and EDTA 
groups. Due to the little amount of control sample loaded, it is possible that the 
citrullination is failing to be detected by the antibody. This experiment should be 
repeated with equal loading in order to observe differences between the two groups (+ 
calcium and + EDTA). 
 
3.5.2. Differences in citrullination between HS-5 and HEK293T cells lines treated 
with recombinant PADI2 
As the result of using a truncated version of PADI2, full-length baculovirus expressed 
recombinant PADI2 was obtained whilst a full-length active and inactive mutant 




For each of the HS-5 and HEK293T cell lines, cells were lysed using a sonicator and 
the soluble fraction split between three tubes and left untreated (lysate), treated with 10 



















Figure 3.5.3. –  Full-length recombinant PADI2 has little effect on citrullination in HS-5 
and HEK293T cell lines. Immunoblot analysis of cell lysates, cell lysates treated with 
calcium alone (10 mM) and cell lysates with calcium (10 mM) and recombinant PADI2 
(130 nM). Each reaction was stopped with SDS-PAGE sample buffer. Samples were 
separated using a 10% SDS-PAGE gel and probed with anti-citrulline. 
 
Both HS-5 and HEK293T cell lines continue to present obvious bands at a size of ~102 
kD and ~30 kD as seen in previous experiments. Due to no anti-β-actin loading control, 
it is difficult to conclude the findings, but it is likely the case that HEK293T cells show 
increased citrullination due to a larger amount of sample loaded. Furthermore, HS-5 
cells appear to produce bands at approximately 150 kD and 17 kD, whereas none 
appear to be visible at this size in HEK293T cells. It is possible this could be unique to 
HS-5 cells due to the assumption of more HEK293T sample loading. On the other 
hand, from this immunoblot, it is difficult to infer whether there is any change within 
each group alone, as citrullination appears to remain the same and produce no 




immunoprecipitation was carried out to enrich for citrullinated proteins from the HS-5 
cell line treated with recombinant PADI2. 
 
3.5.3. Citrullination changes after anti-citrulline immunoprecipitation of 
calcium/EDTA assay in HS-5 cell line when treated with recombinant PADI2 
To analyse the effect of citrullination caused by recombinant PADI2 in HS-5 cells, a 
calcium/EDTA assay was carried out (as described in section 3.5.1), followed by an 
anti-citrulline immunoprecipitation (figure 3.5.4). 
 
Figure 3.5.4. – Calcium and recombinant PADI2 treated HS-5 cells have increased 
citrullination compared to those treated with EDTA. Immunoblot analysis of HS-5 
soluble lysate, split between two eppendorfs and treated with 10 mM calcium 
(Ca2+)/130 nM PADI2 and 1 mM EDTA and soluble lysate anti-citrulline 
immunoprecipitation (IP) treated with 10mM Ca2+/130 nM PADI2 and 1 mM EDTA, 
each incubated for 2 hours at 37°C. Each reaction was stopped with SDS-PAGE 
sample buffer. Samples were separated using SDS-PAGE gel (10%) analysis and 
probed with anti-citrulline. (A) Short exposure. (B) Long exposure. (*) Represents 
bands significant to added calcium and PADI2 in comparison to EDTA. 
 
Here, it is important to note that although there is not an anti-β-actin loading control, the 
same lysate was split between two tubes equally (400μL); therefore, we expect loading 




Within the lysate, it appears that there is increased citrullination within the calcium and 
PADI2 treated cells, where it is decreased in the presence of EDTA (as seen in figure 
3.5.4 A). This trend continues to be the case after immunoprecipitation. It is visible in 
figure 3.5.4 B that there are bands unique to the soluble lysate immunoprecipitation 
treated with calcium and PADI2, as indicated (*). Nonetheless, the band seen with 
short exposure at approximately 45 kD is over exposed with long exposure, suggesting 
the presence of a strongly citrullinated protein. This makes it difficult to analyse other 
citrullinated proteins around 35-52 kD in size. However, long exposure is necessary to 
detect differences in other citrullinated proteins outside of this size region. 
 
3.5.4. The differences in citrullination after anti-citrulline immunoprecipitation of 
calcium/EDTA assay in HS-5 cell line treated with recombinant PADI2 and eluted 
with glycine 
The same assay was repeated with an additional glycine elution step to remove the 
protein from the beads after immunoprecipitation in an attempt to remove the heavy 



















Figure 3.5.5. – Calcium and recombinant PADI2 treated HS-5 cells have increased 
citrullination compared to those treated with EDTA. Immunoblot analysis, treated as 




immunoprecipitation (IP). Each reaction was stopped with SDS-PAGE sample buffer. 
Samples were separated using SDS-PAGE gel (10%) analysis and probed with anti-
citrulline. (*) Represents bands significant to added calcium and PADI2 in comparison 
to EDTA. 
 
Due to over-exposure, it is difficult to analyse the differences between bands 
thoroughly. It is clear that, as seen previously (figure 3.5.4), although there is some 
citrullination occurring with added EDTA after immunoprecipitation, there are obvious 
differences when compared to cells treated with calcium and PADI2, as indicated (*) in 
figure 3.5.5. The glycine elution step unfortunately does not help make the immunoblot 
clearer. It is possible that the strong band, as seen formerly in figure 3.5.4 B, is a 
strongly citrullinated protein. Therefore, this experiment needs to be repeated, loading 
less of each sample to avoid over exposure, as there may be some differences visually 
blocked by this band. 
 
3.6. HEK293T cell line transfected with PADI2 wild type and PADI2 C645S 
mutant  
To understand citrullination changes in PADI2 WT compared to the C645S mutant 
(inactive version), both were cloned into a mammalian expression vector, pCMV-
Tag2B, so that a FLAG-tag sequence was added to the N-terminus of PADI2. Both 
PADI2 WT and mutant were successfully transfected into HEK293T cells using jetPEI® 
transfection reagent. After separating using a 10% SDS-PAGE gel, samples were 
analysed by immunoblotting (figure 3.6). 
 
First, the immunoblot was probed with anti-PADI2 to check for a successful 
transfection. Once it was evident both WT and mutant transfected cells were 
expressing PADI2, the blot was probed with anti-citrulline. Citrullinated proteins appear 
to be present in each sample, although it is noticeable that the PADI2 mutant has less 
citrullination. In support of this, from the loading control, there is possibly less PADI2 
WT loaded, strengthening the possibility that PADI2 mutant produces less citrullination. 
Although, it is difficult to confirm that citrullination changes from figure 3.6, therefore, 
further tests including the use of a PADI inhibitor such as Cl-Amidine should be 





























Figure 3.6. – HEK293T cell line lacks endogenous expression of PADI2, although 
successfully expresses transfected PADI2 wild type (WT) and inactive mutant (C645S). 
When probed for citrullination, it is visible that there is less citrullination present in the 
inactive mutant version of PADI2, as predicted.  Immunoblot analysis of HEK293T cell 
line transfected with PADI2 wild type and PADI2 inactive mutant, using jetPEI® 
transfection reagent. Samples were separated by a 10% SDS-PAGE gel and probed 
with anti-PADI2 (Abcam), anti-citrulline and loading control anti-β-actin. 
 
3.7. Hypoxia 
3.7.1. PADI2 expression is induced in HS-5 cell line in hypoxic conditions 
As Sambandam and colleagues (2004) found that astrocytes have increased PADI2 
















Figure 3.7. – PADI2 expression is increased after, at most, 6 hours and maintained in 
hypoxia (1% oxygen). Immunoblot analysis of HS-5 cell line seeded at 2.5 x 106 and 
placed in hypoxia for 2, 4, 6, 24 and 32 hours. Cells were scraped into 1x Laemmli 
buffer (SDS-PAGE sample buffer) in hypoxic conditions, separated by a 10% SDS-
PAGE gel and probed with anti-PADI2 (Abcam) and loading control anti-β-actin. 
 
Figure 3.7 and figure 3.7.1 show two examples of changes to PADI2 expression after 
incubating HS-5 cells in hypoxia (1% oxygen) for different lengths of time. In figure 3.7, 
it appears that PADI2 expression is increased after six hours in hypoxic conditions; 
however, as demonstrated in 3.7.1, in separate experiments PADI2 expression is 
increased after two hours in hypoxic conditions. This is probably due to the uneven 
loading, represented by the loading control (anti-β-actin), as the two hour and four hour 
samples in figure 3.7 both have less protein loaded. Overall, it appears that hypoxia 






























Figure 3.7.1. – PADI2 expression is induced after only 2 hours in hypoxia conditions. 
Immunoblot analysis of HS-5 cell line seeded at 2.5 x 106 and placed in hypoxia (1% 
oxygen) for 2, 4, 6, 24 and 32 hours. BT474 is a positive control, known to express 
PADI2 under normal conditions. Cells were scraped into 1x Laemmli buffer (SDS-
PAGE sample buffer) in hypoxic conditions and separated by a 10% SDS-PAGE gel. 



























In addition to its strong implication in the autoimmune disease RA, PADI2 has also 
been linked to cancer and other inflammatory diseases including psoriasis (György et 
al., 2006), alzheimers disease (Ishigami et al., 2005) and MS (Vossenaar et al., 2003). 
In fact, it has been suggested that RA patients may be at a higher risk of MM 
development (Shen et al., 2014). Given the similarities in the physiology of RA and 
MM, what is known about the role PADI2 plays in RA could be transferred to MM to 
help identify the effect citrullination has on BMSCs within the BM microenvironment. 
This will ultimately aid our understanding of the disease and potentially yield future 
novel therapeutic targets. Studies investigating PADI activation, their substrate 
specificities and therefore their citrullinating effect, are currently of high priority (Darrah 
et al., 2012). In this study, the aim was to determine the nature of proteins being 
citrullinated in BMSCs, the potential effect that these proteins have within the BM 
microenvironment, and to determine the changes that occur in PADI2 expression in 
BMSCs under hypoxic conditions. 
 
This study revealed changes in citrullination as the result of analysing HS-5 (BMSC cell 
line) cell lysates treated with recombinant PADI2 and excess calcium or with EDTA. 
The PADI2 DNA used in the initial calcium/EDTA assays was a truncated version and, 
therefore, cells ectopically expressing PADI2 did not produce accurate results. It was 
found that endogenous PADI2 expression is upregulated after just two hours in hypoxia 
and this expression is maintained for 32 hours (figure 3.7.1).  
 
4.1. Calcium/EDTA assay 
Before it was discovered that the PADI2 DNA was a truncated version, it was difficult to 
determine why two bands were detected (figure 3.3 A). Endogenous PADI2 (~75 kD) 
immunoprecipitated from PADI2 transfected HEK293T cells revealed an additional 
band present at approximately 50 kD. Initially it was thought that the 75 kD band was 
the transfected PADI2 DNA, however, this became less likely when the previous 
transfection immunoblot was analysed (figure 3.2). Citrullinated proteins observed until 
the PADI2 DNA was sequenced, was the result of endogenous PADI2, as the 
truncated version is missing the important catalytic domain, as demonstrated in figure 
3.4. This therefore, would not have a citrullination effect. Although, calcium/EDTA 
assays conducted before this produced some very interesting results. PADI2 
transfected HEK293T cells show increased citrullination over time, until 60 minutes 




dominant negative effect, allowing endogenous PADI2 to citrullinate proteins before it 
begins to change the activity, where the decline becomes noticeable. This hypothesis 
is supported by the results of the control cells (non-transfected HEK293T cells), as they 
continue to express citrullinated protein for longer. 
 
Proteins that are most commonly known to be citrullinated include: vimentin (Bang et 
al., 2007), α-enolase (Kinloch et al. 2005), fibrinogenβ (Zhao et al., 2008), fibrinogenγ 
(van Steendam et al., 2010), fibronectin (Chang et al., 2005), collagen type II (Yoshida 
et al., 2006), filaggrin (Union et al., 2002), β-actin (Darrah et al., 2012) and histone H3 
(Wang et al., 2009). Although this study is yet to identify proteins by mass spectrometry 
(due to time constraints), similar bands consistently appeared around 230 kD, 100 kD, 
50 kD, 40 kD, 25 kD and 17 kD and were observed throughout the different 
calcium/EDTA assay immunoblot results. After the first calcium/EDTA assay, proteins 
approximately 230 kD, 100 kD, 50/60 kD and 17 kD were identified with calcium 
stimulation. However, further bands of around 50 kD, 40 kD and 25 kD were identified 
with added EDTA, which is surprising given that EDTA should inhibit PADI2 activity. By 
comparing the results to other studies it is possible to predict the type of proteins likely 
to have been citrullinated in this study. In a study by Bang et al. (2007) citrullinated 
vimentin was identified at approximately 50 kD, which is also present in the results of 
this study (figure 3.5 C). Although, citrullinated α-enolase is also a protein of similar 
size at approximately 47 kD (Kinloch et al., 2005), as is filaggrin at 50 kD (Union et al., 
2002). Filaggrin was found in the study by Union and colleagues (2002), to be present 
at 50 kD yet, also has an additional band at 25 kD. A band seen at 25 kD is present in 
figure 3.5 C + EDTA. Fibrinogenγ is around 100 kD (demonstrated by van Steendam et 
al., 2010), as is a band of that size in figures 3.5 and 3.5.1. Lastly, a 17 kD band is 
visible in figure 3.5 C, suggesting a possible citrullinated histone. Citrullinated histone 
H3 has been found by Wang et al. (2009) to be 17 kD when cells are activated with 
calcium, as it is here (figure 3.5 C). When the experiment was repeated (figure 3.5.1), 
the main bands were 100 kD, 40 kD and 25 kD in size with no change between the 
calcium stimulated and EDTA groups. This suggests that fibrinogenγ, β-actin and 
filaggrin were potentially key citrullinated proteins. β-actin was found to be citrullinated 
by PADI2 in cell lysates by Darrah et al. (2012), supported by van Beers et al. (2013) 
who found citrullinated β-actin epitopes in RA serum, although these were identified by 
ELISA as the antibody was unable to detect citrullinated β-actin during 
immunoprecipitation. Moreover, mass spectrometry analysis must be carried out to 




specifically for these potential citrullinated proteins from citrullination 
immunoprecipitates. 
 
Based on the hypotheses that proteins such as vimentin, fibrinogen and α-enolase are 
citrullinated in this study, it could indicate changes occurring that cause an 
inflammatory response (Wegner et al., 2010), directly relevant to what is known about 
the characteristics of MM. Also, citrullination of histones, possibly present in this study, 
is interesting, as this has been previously implicated with NETosis, tumourigenesis and 
early stage inflammation (demonstrated in table 1.1) (Chirivi et al., 2013). 
Nevertheless, this speculation must be confirmed by mass spectrometry analysis. 
 
Changes in citrullination in the HS-5 cell line (after immunoprecipitation of cell lysates) 
were clearly visible between cells treated with recombinant PADI2 and calcium 
compared to EDTA. The trend remains, with bands appearing around 17 kD (histone), 
25 kD (filaggrin), 40 kD (β-actin), 100 kD (fibrinogenγ) and 250 kD (fibronectin) as 
described previously (figure 3.5.3). It was initially thought that the bands were difficult 
to distinguish as the result of either the heavy and light chains remaining from the 
antibody. Therefore, a glycine elution was carried out to remove the protein from the 
protein G sepharose beads to ensure no antibody was remaining. However, strong 
bands remained in the central region of approximately 38-52 kD in size, suggesting a 
strongly citrullinated protein was present within this region. In a normal cellular context, 
PADI2 will only citrullinate specific substrates; however, it has been shown that, if 
PADIs have access to only purified substrate, most of them have the ability to 
citrullinate it (Darrah et al., 2012). It is important to note that cells were lysed and thus 
PADI2 had full access to the cellular content regardless of substrate localisation and 
may, therefore, citrullinate non-physiologically relevant substrates. 
 
The addition of EDTA to HEK293T cells failed to have the desired effect of preventing 
protein citrullination unlike in the study by Assohou-Luty et al. (2014), (from which the 
assay was adopted) where citrullination is prevented by the addition of EDTA. 
However, this may be the result of Assohou-Luty et al. using COS-1 cells, where 
citrullinated proteins cannot be detected under normal calcium conditions, in 
comparison to the HEK293T cells used in this study. EDTA is a calcium chelator, 
chelating only free calcium ions. As little is known about PADI2, it is not clear how 
quickly it binds to available calcium, and so, this may explain why EDTA showed little 
effect in the first instance. Thus, recombinant PADI2 was a better approach, as it is free 




clear difference in citrullination, indicated in figure 3.5.3, during the calcium/EDTA 
assay that used non-transfected cell lysates and alternatively adding in recombinant 
PADI2 and calcium/EDTA, when compared to the effect cells ectopically expressing 
PADI2 (although truncated) have on citrullination, after an immunoprecipitation to 
enrich for citrullinated proteins was performed. Furthermore, rather than transfecting 
PADI2 into HS-5/HEK293T cells, harvesting and treating the lysate with calcium to 
activate PADI2, a better approach demonstrated by Darrah et al. (2012), may be to 
activate endogenous PADI2 using ionomycin as it increases the level of calcium 
intracellularly. In the study by Darrah and colleagues (2012), citrullination was greatly 
induced after a four-hour incubation period with ionomycin, compared to their control 
cells (neutrophils) that did not show any signs of citrullination. 
 
4.2. PADI2 expression in hypoxia 
In the first instance, it appeared that PADI2 was not expressed in hypoxic conditions 
until six hours (figure 3.7). Although due to unequal loading it was difficult to conclude 
from this. Therefore, the experiment was repeated. A BCA assay was not performed, 
which resulted in less accurate protein quantification, and therefore less accurate 
loading. The reason for this was to prevent reoxygenation of the cells. Thus, the 
samples were scraped directly into an equal amount of SDS-PAGE sample buffer (1x 
Laemmli) and boiled. From the results of the second experiment (figure 3.7.1), it 
became clear that PADI2 expression was induced by two hours in hypoxia and 
maintained for at least 32 hours. Thus, our initial investigations suggest that hypoxia 
does play a role in PADI2 expression. PADI2 expression was expected to increase in 
hypoxia after Sambandam and colleagues (2004) found that PADI2 was markedly 
increased in astrocytes after eight hours in hypoxic conditions, with PADI2 mRNA 
levels increased and maintained after just two hours. This later resulted in increased 
protein citrullination.  
 
Hypoxic conditions in MM increase expression of the chemokine receptor, CXCR4 
present on the surface of MM cells. This allows circulating malignant plasma cells to 
home to new areas of the BM (Azab et al., 2012). Hypoxia activates EMT machinery by 
decreasing CDH1 expression allowing metastasis to take place (Azab et al., 2012). 
Therefore, it is interesting that PADI2, and consequently citrullination, is increased in 
hypoxic conditions, and may potentially play a role in changing the adhesion process, 
as it does within the synovial joint of RA patients, demonstrating a crucial role in the 
homing process. Shelef et al. (2012) report that increased citrullination of proteins such 




adhere and migrate within the rheumatoid joint of a RA patient. From the findings in this 
study and from knowledge gathered in previous studies, it appears that BMSCs in an 
increasingly hypoxic environment eventually lead to an increase in PADI2 expression 
and as a result, aberrant citrullination. In terms of MM, it is possible that when the 
malignant plasma cells within the BM microenvironment become hypoxic, PADI2 is 
increased causing aberrant citrullination in the BMSCs, and ultimately affects their 
ability to spread, migrate and adhere to the BM. To determine whether this hypothesis 
is correct, further experiments need to be repeated to confirm the findings in this study, 
not only in HS-5 (BMSC cell line) cells but also in BMSCs obtained from MGUS and 
MM patients.  
 
4.3. Conclusions and future work 
In this study, differences were observed in citrullination between HS-5 cells treated with 
recombinant PADI2 and calcium compared to added EDTA. However, added EDTA did 
not have the desired effect of inhibiting all or most citrullination, as it was still present. 
This may be due to the concentration (1 mM) added, and therefore, increasing the 
amount of EDTA added may help in repeat experiments. Additionally, during this 
assay, significantly less recombinant PADI2 (130 nM) was used compared to the 
experiment by Darrah et al. (2012) who used 700 nM. It would be beneficial to increase 
the amount of recombinant PADI2 added to each experiment. As discussed above, 
treating with ionomycin may be a more effective approach to stimulate PADI2 
expression, and therefore, citrullination.  
 
The PADI2 DNA in this study was a truncated version, it is therefore important that the 
calcium/EDTA assays should be carried out using full-length PADI2 in order to 
determine the true effects of citrullination. 
 
Owing to issues with unequal loading, visualising each immunoblot using a LI-COR 
Odyssey system would provide a better, quantitative method for imaging than the 
chemiluminescence technique used in this study. As a BCA assay was not carried out 
to protein quantify before loading onto an SDS-PAGE gel, a LI-COR Odyssey system, 
which gives a linear signal, may provide a more accurate approach to obtaining a true 
result by normalising to the loading control. 
 
The citrullination antibody used in this study was the whole antiserum. Therefore, it has 
a lot of background present and there is potential that it binds to non-specific proteins. 




or very little citrullination present, and consequently would indicate the specificity of the 
antibody. Additionally, an shRNA experiment for the long-term gene knockdown of 
PADI2 in HS-5 or MGUS/MM patient fibroblast cells would enable the specificity of 
PADI2 antibodies used in this experiment to be checked. This is an experiment that 
could be carried out in normal conditions, but also in hypoxia, to identify whether PADI2 
expression remains to be increased. 
 
It would also be interesting to measure the mRNA levels of PADI2 in BMSCs during a 
progressively hypoxic environment, as Darrah et al. (2012) established that PADI2 
mRNA expression is increased and maintained throughout a sixteen hour time window 
after two hours under hypoxic conditions. Additionally, treating non-transfected HS-5 
cells or MGUS/MM patient cells with ionomycin in hypoxia to encourage endogenous 
expression of PADI2, and therefore stimulate citrullination may prove interesting, as it 
will allow citrullinated proteins, produced as the result of hypoxia, to be identified. This 
would enable the aberrantly citrullinated proteins in the BM microenvironment to be 
mimicked in vitro more closely to the physiological BM microenvironment in vivo. 
 
Once specific substrates have been identified as the result of mass spectrometry 
analysis, it would be attractive to identify if these same proteins are citrullinated in 
BMSCs of MGUS and MM patients as the result of increased PADI2 expression and 
determine the significance of citrullinated protein activity in the context of MM.  
Ultimately, the first step would be to determine if MGUS and MM patient BMSCs show 
increased citrullination and to carry out calcium/EDTA assays and hypoxia experiments 
in these cells to determine the proteins aberrantly citrullinated. To investigate this 
further, co-culture experiments (possibly performed at different oxygen tensions) to 
partially mimic the BM microenvironment in vitro, utilising JJN3 and H929 MM cells, 
could be performed to determine the effect of these citrullinated proteins on MM cell 
phenotypes, for example, MM cell proliferation or cell survival.  
 
Overall, further investigation into the role of citrullination in the BM microenvironment in 
MM remains, but this study has provided the initial steps in understanding the effect 
that changes in PADI2 expression has on BMSCs. Continuing from this study will be 
the mass spectrometry confirmation of which citrullinated proteins are present. This will 
unveil future potential targets for research/therapy and to aid our understanding of the 
effect aberrant citrullination has on the behaviour of BMSCs within the BM 
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